For the first time, most Americans using GLP-1 drugs say they use them to lose weight, not to treat diabetes.
Story Snapshot
- Weight-loss users now make up 54% of GLP-1 users in the United States.
- EY-Parthenon’s report points to a mainstream shift in why people seek these drugs.
- Food and retail habits are changing as users buy less snack food and alcohol.
- Use of GLP-1 drugs has risen fast across the population since 2023.
Weight Loss Surpasses Diabetes As The Lead Reason
Consulting firm EY-Parthenon reports that weight-management users now represent 54% of United States GLP-1 users, overtaking those using the medicines for diabetes or other health reasons. This marks a pivot in public demand. These drugs started as a diabetes treatment with weight loss as a side benefit. Now the center of gravity has moved. People seek the drugs for slimming first, and for glucose control second. That switch has consequences across healthcare, food, and finance.
Major outlets amplified the shift, noting how it affects what people buy and wear, from groceries to clothing sizes. The message lands because it matches what many households see. Families know someone on these drugs. The shopping cart changes. So do habits at restaurants. A clear headline number ties it together: a majority now use GLP-1 drugs for weight loss. That number gives leaders and payers a new baseline for choices on coverage, supply, and patient support.
How Fast Adoption Fuels A Consumer Ripple
Rapid adoption sets the stage for broad effects. Academic and market research tracked a jump in United States usage from about five and a half percent of adults in fall 2023 to more than eight percent by mid-2024, with later surveys showing even higher reach by 2026. Rising use shifts household spending. Studies link GLP-1 use to lower grocery bills and fewer snack and alcohol purchases, along with more protein and nutrient-dense foods. That dents some brands and rewards others that meet new demand.
Retailers now plan for leaner baskets and smaller sizes. Apparel buyers watch returns fall as waistlines shrink. Food makers test high-protein lines, change pack sizes, and reset promotions. This is not hype. A simple change in appetite adds up across millions of customers. Consumers who feel full sooner skip impulse snacks. For companies built on volume, that is a direct hit. For firms that pivot fast, it is an opening to gain share with better-for-you options that fit these new routines.
Why The Split Matters For Policy And Care
The shift from diabetes-first to weight-first users forces fresh choices on coverage and access. Employers and insurers must decide which patients qualify, for how long, and at what cost. The logic that guided diabetes coverage does not map cleanly to weight loss alone. Yet obesity drives heart disease, joint failure, sleep apnea, and liver disease. Targeted coverage could reduce later costs, hospital stays, and lost work. That lines up with common sense: invest early to avoid bigger bills later.
Doctors also face new workflows. Many patients have both diabetes and obesity and may benefit on two fronts. Others seek weight loss only. Clear pathways for screening, drug choice, and follow-up can prevent waste and side effects. Transparent goals matter. If the aim is sustainable weight loss, plans should pair medicine with diet, sleep, strength training, and counseling. That reduces drop-offs and rebounds. It also respects the patient’s time and money, two values that should guide any serious health policy.
What The 54% Tells Business Leaders To Do Next
Leaders should treat the 54% figure as a signal, not a fad. Food makers need product pipelines for smaller portions, higher protein, and lower sugar. Retailers should recalibrate shelf space and rethink promotions that once relied on impulse buys. Apparel brands should adjust size runs and fit blocks as average measurements shift. Insurers and employers should pilot value-based coverage that rewards real outcomes, not endless refills. Shareholders should ask management how plans adapt to a world that snacks less and meal-plans more.
🔴 54% of GLP-1 users now take drugs for weight loss, not diabetes
Weight loss has surpassed all other medical uses of semaglutide medications such as Ozempic and Wegovy, according to survey data from EY-Parthenon covering 3,602 current or former GLP-1 users.
Consumers on the… pic.twitter.com/SNQjW5P5Ex— NewsTongue (@NewsTongueX) October 23, 2026
Markets move when habits harden. The rise in GLP-1 use since 2023 suggests this is more than a blip. For households, the test is simple: does life get better, cheaper, and easier? Policies that expand access for high-risk patients, protect supply from shortages, and cut red tape earn trust. Companies that help customers stay on track with simple, honest tools will win repeat business. Change came fast. The winners will be those who move faster, guided by the facts now on the table.
Sources:
cbsnews.com, foodinstitute.com
